HRTX Heron Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HRTX

Price (delayed)

$2.65

Market cap

$398.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.8

Enterprise value

$549.32M

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...

Highlights
Heron Therapeutics's EPS has surged by 52% YoY and by 13% QoQ
Heron Therapeutics's net income has increased by 39% YoY and by 8% from the previous quarter
The equity has declined by 22% since the previous quarter
The debt is up by 14% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://herontx.com
Peers: DRRX ALKS LGND PCRX

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
150.33M
Market cap
$398.37M
Enterprise value
$549.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.32
Earnings
Revenue
$127.04M
EBIT
-$110.06M
EBITDA
-$107.16M
Free cash flow
-$60.32M
Per share
EPS
-$0.8
Free cash flow per share
-$0.44
Book value per share
-$0.23
Revenue per share
$0.92
TBVPS
$1.61
Balance sheet
Total assets
$222.51M
Total liabilities
$256.48M
Debt
$179.63M
Equity
-$33.97M
Working capital
$109.09M
Liquidity
Debt to equity
-5.29
Current ratio
2.37
Quick ratio
1.76
Net debt/EBITDA
-1.41
Margins
EBITDA margin
-84.3%
Gross margin
48.8%
Net margin
-87%
Operating margin
-87.1%
Efficiency
Return on assets
-50.6%
Return on equity
N/A
Return on invested capital
-39.4%
Return on capital employed
-77.1%
Return on sales
-86.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
-5.36%
1 week
-4.33%
1 month
-10.77%
1 year
-0.38%
YTD
55.88%
QTD
-4.33%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$127.04M
Gross profit
$61.94M
Operating income
-$110.62M
Net income
-$110.56M
Gross margin
48.8%
Net margin
-87%
The net margin is up by 49% year-on-year and by 11% since the previous quarter
HRTX's operating margin is up by 46% year-on-year and by 11% since the previous quarter
Heron Therapeutics's net income has increased by 39% YoY and by 8% from the previous quarter
The operating income has increased by 37% year-on-year and by 8% since the previous quarter

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.32
Heron Therapeutics's EPS has surged by 52% YoY and by 13% QoQ
The equity has declined by 22% since the previous quarter
HRTX's price to sales (P/S) is 92% more than its last 4 quarters average of 1.5 but 68% less than its 5-year quarterly average of 9.0
HRTX's revenue is up by 18% year-on-year and by 3.4% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has increased by 49% YoY and by 11% QoQ
The ROIC has grown by 39% YoY and by 6% from the previous quarter
HRTX's ROA is up by 28% YoY and by 4.7% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 13% lower than its total liabilities
Heron Therapeutics's total assets has decreased by 11% YoY and by 2.9% QoQ
HRTX's total liabilities is up by 8% year-on-year
The debt to equity has dropped by 146% year-on-year but it is up by 18% since the previous quarter
The equity has declined by 22% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.